The Melanoma Research Alliance (MRA), the largest private funder of melanoma research, today announced grant awards of more than $13 million to conduct cutting-edge melanoma research. The awards include $7.5 million from MRA’s research funds, and an additional $5.6 million obtained through the added leverage of MRA’s innovative collaborative funding program with companies, institutions, and foundations.
MRV Research
MELANOMA TREATMENT TO BE PBS-LISTED
MSD has welcomed the Federal Government’s announcement that patients with the most deadly form of skin cancer – advanced melanoma – will be able to access the company’s anti-PD1 immunotherapy (pembrolizumab) on the PBS.
TGen and Mayo Clinic help launch national clinical trials to combat advanced skin cancer
Arizonans will receive benefit from recently FDA-approved precision medicine clinical trial to fight deadly melanoma
Moffitt researchers discover mechanism leading to BRAF inhibitor resistance in melanoma
The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining cells adapt to treatment and become resistant. Moffitt Cancer Center researchers have discovered a novel mechanism that can lead melanoma cells to develop resistance to drugs that target the protein BRAF.